RAS Mutation Status and Immune Microenvironment in pMMR Colorectal Cancer

225 patient records from a retrospective study of proficient mismatch repair colorectal cancer. Multiplex immunohistochemistry quantified immune cell densities and protein expression to define prognostic and predictive biomarkers. The dataset, authored by Shigang Wu, was last updated on 2026-05-07.

Use Cases

• Identify prognostic subgroups based on RAS mutational status and immune cell infiltration.
• Predict chemotherapy benefit using biomarkers like CD163+ macrophage density.
• Analyze the interplay between stromal CD4+ T-cells and survival in RAS wild-type tumors.
• Validate the role of β-catenin and CMTM6 expression as modifiers of treatment response.

Strengths

• Includes data from 225 patients with pMMR colorectal cancer.
• Quantifies multiple immune cell types (CD4+, CD8+, CD68+, CD163+) and proteins (β-catenin, CMTM6, PD-L1).
• Results include formal interaction testing with hazard ratios, such as HR=0.20 for the CD163-high subgroup.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data may reflect temporal and methodological bias inherent to a single retrospective study.

Provenance

Source

figshare, author Shigang Wu.

Collection Method

Retrospective analysis using multiplex immunohistochemistry on patient samples.

Freshness

Last updated 2026-05-07 04:45:33; freshness should be verified.